Clinical Trial Detail

NCT ID NCT02605915
Title Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Atezolizumab + Trastuzumab

Docetaxel

Carboplatin

Pertuzumab

Age Groups: adult

Additional content available in CKB BOOST